How can researchers expand a chiral ligand library beyond familiar diol frameworks? A study from Jianwei Sun's group at the Hong Kong University of Science and Technology introduces SPHENAM and NOSPHEN, two nitrogen-containing spirocyclic scaffolds. Their significance lies in both the functional groups they offer and the routes used to build them. For researchers evaluating chiral building blocks, the work provides a useful starting point for thinking about scaffold diversity, synthesis and screening.

Research summary: a route to nitrogen-containing spiro scaffolds

Ronghua Zhang, Minghui Zhu and Jianwei Sun reported the work in the Journal of the American Chemical Society in 2025. SPHENAM is a spirocyclic diamine; NOSPHEN combines an amine with a phenolic hydroxyl group. Both are amine analogues of SPHENOL, rather than alternative names for SPINOL.

The researchers constructed these frameworks without first preparing the parent spiro diol. One approach used chiral phosphoric acid catalysis to control spirocyclization. A complementary route introduced additional backbone substituents through rhodium-catalyzed chemistry. Together, the approaches enabled access to structurally varied derivatives.

Initial applications included rhodium-catalyzed asymmetric hydrogenation, palladium-catalyzed asymmetric allylic substitution and a Morita-Baylis-Hillman reaction. Selected derivatives performed favorably against the comparison catalysts or ligands in the reported experiments. These findings support further screening; they do not establish superiority across every substrate or reaction. Read the original study.

COMORA commentary: what should researchers take from this work?

Our interpretation is that the most useful lesson is to consider synthetic accessibility alongside molecular design. A promising scaffold becomes more practical to investigate when researchers can obtain several related structures and compare them under consistent conditions.

For a screening project, it is helpful to separate three questions. Which parent framework is being tested? Which functional groups are being introduced? Which final catalyst or ligand will actually enter the reaction? A result obtained with a derived ligand should not automatically be assigned to its unmodified building block.

The same distinction matters when comparing SPINOL with SPHENAM or NOSPHEN. Similar interest in spiro chirality does not make these compounds interchangeable. Researchers should check the complete structure, functional-group arrangement and stereochemical assignment before choosing a starting material or requesting a quotation.

A useful next experiment would compare candidate ligands on the team's own representative substrates, using a common reference catalyst. Yield, enantiomeric excess, catalyst loading and isolation should be considered together. A favorable result on one model substrate is a reason to investigate further, rather than a prediction of performance throughout a development program.

From a published scaffold to a practical procurement request

Before purchasing a chiral spirocyclic building block, define the target as precisely as possible. This reduces ambiguity between related frameworks, enantiomers and protected derivatives.

  • Provide a structure file or drawing, chemical name and CAS number where available.
  • Specify the required enantiomer and whether chemical purity and enantiomeric purity need separate acceptance criteria.
  • State the intended derivative or reaction so that the required functional groups are clear.
  • Include the initial screening quantity and any anticipated follow-up quantity.
  • Identify the analytical documentation needed, such as a COA, identity data or a chiral chromatographic report.

For a target outside the current catalog, route feasibility, analytical requirements and delivery expectations should be evaluated before the compound is included in a screening schedule.

COMORA spirocyclic building blocks and related product series

COMORA supplies selected spirocyclic building blocks and chiral chemistry products, with customer-defined derivatives available for technical evaluation. The current catalog includes the following product groups.

SPINOL building blocks

The SPINOL and chiral ligand series includes R-SPINOL, CAS 223259-62-9, S-SPINOL, CAS 223259-63-0 and SPINOL, CAS 223137-87-9. These products provide starting points for projects involving chiral scaffold modification and ligand development. Enantiomer, specification and analytical requirements should be confirmed for each inquiry.

Functionalized spirobiindane intermediates and ligands

The catalog also lists dibromo-substituted spirobiindane diols, spirobiindane dicarboxylic acid derivatives and spirobiindane-based bisphosphine ligands. These groups extend the available choices beyond the parent diol. Selection should be based on the exact target structure and proposed synthetic route; current availability and documentation are confirmed on request.

Other spirocyclic product families

COMORA's broader catalog includes an azaspiro carboxylic acid building block and functionalized spirobifluorene products, including brominated and boronic acid derivatives. These are separate scaffold families serving different research needs. They should be selected by structure and application rather than grouped together solely because they contain a spiro center.

Discuss your spirocyclic target with COMORA

For SPINOL products, related intermediates or a customer-defined spirocyclic target, contact [[email protected]](mailto:[email protected]) with the structure, desired stereochemistry, quantity and specification. COMORA can review catalog options or evaluate a custom synthesis request.

The SPHENAM and NOSPHEN structures discussed in the research section are not presented here as confirmed COMORA catalog products. Requests involving these or other newly reported structures require an individual technical and supply assessment.

References and editorial attribution

  • Zhang, R.; Zhu, M.; Sun, J. Design, Synthesis, and Application of a Type of Chiral Spirocyclic Naphthylamines. Journal of the American Chemical Society, 2025, 147 (40), 36774-36780. DOI: 10.1021/jacs.5c12568.
  • X-MOL research coverage, published October 17, 2025, provided the starting point for this editorial.

This article is an original English research summary and commentary prepared for COMORA. Research findings are attributed to the cited authors; the procurement discussion and product introduction are COMORA editorial content.